Home Tags UC-961

Tag: UC-961

Zilovertamab vedotin Demonstrates Encouraging Clinical Activity in B-Cell Cancers

ADC Review | Editorial Team
A novel ROR1-targeted antibody-drug conjugate (ADC), zilovertamab vedotin, also known as  MK-2140 or VLS-101, has demonstrated encouraging clinical efficacy, consistent pharmacokinetics, and a favorable...

Oncternal Therapeutics Announces Closing of an $18.4 million Series B Financing.

Peter Hofland
Clinical-stage biotechnology company Oncternal Therapeutics announced the closing of an $18.4 million Series B financing. The company which develops first-in-class and novel therapies for...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X